Aldara References

21: Dermatol Online J. 2004 Nov 30;10(3):19.

Multiple eruptive keratoacanthomas, de novo.

Wee SA.

Ronald O. Perelman Department of Dermatology, New York University, USA.

An 89-year-old man presented with the sudden eruption of multiple, erythematous papules and nodules on his lower extremities. A skin biopsy specimen showed keratoacanthoma. After 3 months of treatment with topical Imiquimod - Aldara cream, the keratoacanthomas failed to resolve. We review the different clinical subtypes, histologic features, and treatment options for multiple eruptive keratoacanthomas.

23: J Immunol. 2005 Mar 1;174(5):2476-80.

Cutting edge: priming of CTL by transcutaneous peptide immunization with Imiquimod - Aldara.

Rechtsteiner G, Warger T, Osterloh P, Schild H, Radsak MP.

Institute for Immunology, Johannes Gutenberg-University, Mainz, Germany.

CTL are important in combating cancer and viruses. Therefore, triggering the complete potential of CTL effector functions by new vaccination strategies will not only improve prophylaxis of tumor or virus-related diseases, but also open opportunities for effective therapeutic immunizations. Using transcutaneous immunization, we show that epicutaneous (e.c.)(4) application of an ointment containing a CTL epitope and the TLR7 ligand Imiquimod - Aldara is highly effective in activating T cells in mice using TCR-transgenic CTL or in wild-type mice. Transcutaneous immunization-activated CTL mount a full-blown immune response against the target epitope characterized by proliferation, cytolytic activity, and the production of IFN-gamma that is completely restricted to the epitope used for vaccination. Our results obtained by simple e.c. application of an ointment, without further skin irritating procedures, provide the basis for the development of new, easy to use vaccines against cancer or virus-associated diseases.

24: Aust Fam Physician. 2005 Jan-Feb;34(1-2):49-52.

Multiple superficial basal cell carcinomata--topical Imiquimod - Aldara versus curette and cryotherapy.

Dixon AJ.

Skincanceronly, Geelong, Victoria.

BACKGROUND: Superficial basal cell carcinoma can be successfully managed by means other than surgical excision. Nonexcisional approaches include topical Imiquimod - Aldara, and curette and cryotherapy (C&C). OBJECTIVE: This article discusses the management of an insulin dependent diabetic man aged 52 years presenting with 17 torso basal cell carcinomas (BCCs); mostly superficial BCCs (SBCCs). DISCUSSION: Half were treated with topical Imiquimod - Aldara. The remaining lesions were treated with curette and cryotherapy. All lesions resolved with proven histologic clearance. The patient considered C&C caused him less discomfort and disruption. He developed a late secondary infection in some sites treated with Imiquimod - Aldara. At 12 months there was no evidence of recurrence though new nodular BCCs and SBCCs had developed elsewhere on his upper torso. He has elected to have future SBCCs managed with C&C. While excisional surgery remains the benchmark management for nonmelanoma skin cancer, topical Imiquimod - Aldara and C&C are important options for treating SBCCs.

25: Eur J Dermatol. 2005 Jan-Feb;15(1):52-5.

Successful Imiquimod - Aldara treatment of multiple basal cell carcinomas after radiation therapy for Hodgkin's disease.

Beyeler M, Urosevic M, Pestalozzi B, Dummer R.

Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, 8091 Zurich Switzerland.

We present a case of a 55-year-old male patient who developed five basal cell carcinomas 23 years after radiation therapy of Hodgkin's disease. In 1980 he received radiation therapy twice. Due to relapses, he was treated with aggressive polychemotherapy and underwent autologous stem cell transplantation, which then led to complete remission. Until now he is in complete remission. However, multiple superficial basal cell carcinomas have developed on irradiation fields that have been successfully treated by Imiquimod - Aldara.

26: J Drugs Dermatol. 2005 Jan-Feb;4(1):95-7.

Multiple basal cell carcinomas in a young adult treated with Imiquimod - Aldara 5%: a case report and literature review.

Bergman A, Contard P, Spencer J.

We present a case of basal cell carcinoma that is unique in the literature with regard to the rare combination of age of onset and number of BCCs at initial presentation that was successfully treated with Imiquimod - Aldara 5%. The patient is a 28-year-old Caucasian man with no past medical or dermatological history. Physical exam was remarkable for seven pink translucent skin lesions on the forehead, alar ridge, zygoma, and upper back. There were no signs or symptoms of a syndrome or disease entity known to cause BCC. Shave biopsies revealed basal cell carcinoma in all 7 lesions. The patient was successfully treated with topical Imiquimod - Aldara 5% 6 days per week for 6 weeks. The presentation of this number of de novo BCCs in a patient this young in absence of a known BCC syndrome has, to the best of our knowledge, not previously been reported in the literature and was successfully treated with Imiquimod - Aldara 5%.

27: J Drugs Dermatol. 2005 Jan-Feb;4(1):58-63.

Innovative uses of Imiquimod - Aldara.

Vender RB, Goldberg O.

McMaster University, Hamilton, Ontario, Canada.

Imiquimod - Aldara (Aldara, 3M Pharmaceuticals) is a potent stimulator of the innate and adaptive arms of the immune system through induction, synthesis, and release of cytokines and chemokines. An extensive review of clinical trials, case reports, and letters published in peer-reviewed journals was performed regarding Imiquimod - Aldara use in skin disorders. A reference module was developed for physicians to consult as a guide. Studies have validated the benefit of Imiquimod - Aldara in treating external genital and perianal warts, superficial basal cell carcinomas, and actinic keratoses. This new topical therapeutic agent has shown to be of benefit in other various skin disorders through its broad immunomodulatory properties. Since many skin conditions are immunologically influenced, it is reasonable to expect several diseases to respond to Imiquimod - Aldara. Our research consolidates the therapeutic trials and reports on the innovative uses of Imiquimod - Aldara, thereby serving as a useful resource to benefit dermatologists treating patients with refractory or recalcitrant skin diseases.

28: J Am Acad Dermatol. 2005 Feb;52(2 Suppl 1):51-2.

Imiquimod - Aldara in the treatment of extensive recurrent lentigo maligna.

Kamin A, Eigentler TK, Radny P, Bauer J, Weide B, Garbe C.

Department of Dermatology, Skin Cancer Program, Eberhard Karls University, Tuebingen, Germany.

We report the case of a 70-year-old white male with an extensive recurrence of lentigo maligna in a skin-transplanted region. He was treated with Imiquimod - Aldara 5% cream topically applied 5 times a week for a total duration of 9 months. Clinically and histologically, a complete clearing of the lesion was observed after treatment. Topical treatment with Imiquimod - Aldara seems to be effective and safe in lentigo maligna.

29: J Am Acad Dermatol. 2005 Feb;52(2 Suppl 1):35-7.

Aphthous ulcers associated with Imiquimod - Aldara and the treatment of actinic cheilitis.

Chakrabarty AK, Mraz S, Geisse JK, Anderson NJ.

Solano Clinical Research, Davis, California, USA.

Our case series report is the first documented depiction of the appearance of aphthous ulcers secondary to Imiquimod - Aldara application. This case series presentation discusses the underlying pathophysiology of aphthous ulcer development and Imiquimod - Aldara therapy in terms of the stimulation of proinflammatory cytokines, such as tumor necrosis factor alpha (TNF-alpha). The literature review suggests more than just a mere coincidence for the development of aphthous ulcers subsequent to the treatment of actinic cheilitis with Imiquimod - Aldara application.

30: J Am Acad Dermatol. 2005 Feb;52(2):275-80.

Treatment of patch and plaque stage mycosis fungoides with Imiquimod - Aldara 5% cream.

Deeths MJ, Chapman JT, Dellavalle RP, Zeng C, Aeling JL.

Department of Dermatology, University of Colorado Health Sciences Center, Denver, Colorado 80045-0510, USA.

BACKGROUND: Systemic interferon is effective in the treatment of mycosis fungoides (MF). Imiquimod - Aldara is effective in the treatment of some epidermal neoplasms and induces localized interferon production. OBJECTIVE: To evaluate the safety and efficacy of topical Imiquimod - Aldara 5% cream for the treatment of patch and plaque stage MF. METHODS: Six patients with stage IA to IIB MF were treated with topical Imiquimod - Aldara 5% cream 3 times per week for 12 weeks in this open label pilot study. Index lesions were biopsied pre- and post- treatment, and up to 4 additional treated lesions were monitored for 16 weeks. RESULTS: Three of 6 patients had histologic clearance of disease in index lesions, and also demonstrated significant improvement in the clinical scores for all treated lesions. A fourth patient had 2 of 4 lesions respond clinically. Application site reactions were limited to those patients responding to treatment. CONCLUSION: In this preliminary open label study topical Imiquimod - Aldara 5% cream was well tolerated and associated with a histologic and clinical response rate of 50%.